Sessions are scheduled in local time (CEST)

Displaying One Session

View
Hamburg Hall Industry Satellite Symposium

Lilly - Targeted adjuvant strategies for HR-positive HER2-negative early breast cancer: Who can benefit, and how can we optimize their use? (ID 21)

Date
Thu, 11.05.2023
Time
11:30 - 12:30
Room
Hamburg Hall
Chairs
  • Sara A. Hurvitz (Santa Monica, CA, United States of America)
  • Miguel Martin Jimenez (Madrid, Spain)
Lilly - Targeted adjuvant strategies for HR-positive HER2-negative early breast cancer: Who can benefit, and how can we optimize their use? (ID 21)

Welcome and introductions (ID 934)

Lecture Time
11:30 - 11:35
Session Name
Lilly - Targeted adjuvant strategies for HR-positive HER2-negative early breast cancer: Who can benefit, and how can we optimize their use? (ID 21)
Room
Hamburg Hall
Date
Thu, 11.05.2023
Time
11:30 - 12:30
Speakers
  • Sara A. Hurvitz (Santa Monica, CA, United States of America)
  • Miguel Martin Jimenez (Madrid, Spain)
Lilly - Targeted adjuvant strategies for HR-positive HER2-negative early breast cancer: Who can benefit, and how can we optimize their use? (ID 21)

Assessing risk of recurrence in HR-positive, HER2-negative early breast cancer (ID 935)

Lecture Time
11:35 - 11:45
Session Name
Lilly - Targeted adjuvant strategies for HR-positive HER2-negative early breast cancer: Who can benefit, and how can we optimize their use? (ID 21)
Room
Hamburg Hall
Date
Thu, 11.05.2023
Time
11:30 - 12:30
Speakers
  • Sara A. Hurvitz (Santa Monica, CA, United States of America)
  • Miguel Martin Jimenez (Madrid, Spain)
Lilly - Targeted adjuvant strategies for HR-positive HER2-negative early breast cancer: Who can benefit, and how can we optimize their use? (ID 21)

Impact of oral targeted adjuvant therapies in patients with HR-positive, HER2-negative early breast cancer (ID 936)

Lecture Time
11:45 - 11:55
Session Name
Lilly - Targeted adjuvant strategies for HR-positive HER2-negative early breast cancer: Who can benefit, and how can we optimize their use? (ID 21)
Room
Hamburg Hall
Date
Thu, 11.05.2023
Time
11:30 - 12:30
Speakers
  • Sara A. Hurvitz (Santa Monica, CA, United States of America)
  • Miguel Martin Jimenez (Madrid, Spain)
Lilly - Targeted adjuvant strategies for HR-positive HER2-negative early breast cancer: Who can benefit, and how can we optimize their use? (ID 21)

Optimizing adherence and persistence with oral targeted adjuvant therapies in HR-positive, HER2-negative early breast cancer (ID 937)

Lecture Time
11:55 - 12:05
Session Name
Lilly - Targeted adjuvant strategies for HR-positive HER2-negative early breast cancer: Who can benefit, and how can we optimize their use? (ID 21)
Room
Hamburg Hall
Date
Thu, 11.05.2023
Time
11:30 - 12:30
Speakers
  • Sara A. Hurvitz (Santa Monica, CA, United States of America)
  • Miguel Martin Jimenez (Madrid, Spain)
Lilly - Targeted adjuvant strategies for HR-positive HER2-negative early breast cancer: Who can benefit, and how can we optimize their use? (ID 21)

Shared decision-making in HR-positive, HER2-negative early breast cancer: Enhancing patient-provider communication (ID 938)

Lecture Time
12:05 - 12:15
Session Name
Lilly - Targeted adjuvant strategies for HR-positive HER2-negative early breast cancer: Who can benefit, and how can we optimize their use? (ID 21)
Room
Hamburg Hall
Date
Thu, 11.05.2023
Time
11:30 - 12:30
Speakers
  • Sara A. Hurvitz (Santa Monica, CA, United States of America)
  • Miguel Martin Jimenez (Madrid, Spain)
Lilly - Targeted adjuvant strategies for HR-positive HER2-negative early breast cancer: Who can benefit, and how can we optimize their use? (ID 21)

Questions and take-home learnings (ID 939)

Lecture Time
12:15 - 12:30
Session Name
Lilly - Targeted adjuvant strategies for HR-positive HER2-negative early breast cancer: Who can benefit, and how can we optimize their use? (ID 21)
Room
Hamburg Hall
Date
Thu, 11.05.2023
Time
11:30 - 12:30
Speakers
  • Sara A. Hurvitz (Santa Monica, CA, United States of America)
  • Miguel Martin Jimenez (Madrid, Spain)